? COMMUNITY OUTREACH AND ENGAGEMENT Since Duke Cancer Institute?s (DCI) inception in 2011, significant effort has gone into enhancing DCI Community Outreach and Engagement (COE) and addressing cancer health disparities. DCI uses patient data analytics to define its Catchment Area (CA) to the 85th percentile of its patient base, focused primarily on central North Carolina. DCI?s CA cancer burden was defined using a 3-pronged approach: 1) DCI senior leaders served with the State of North Carolina Advisory Committee on Cancer Coordination and Control (NC-ACCCC), the NC Cancer Prevention and Control Branch, and the NC Cancer Registry, to help conduct a county by county analysis of all cancers with a focus on cancers for which NC incidence and mortality rates either exceed the national averages, exhibit significant disparities, and/or are preventable; 2) DCI created a 20-member Community Advisory Board representing its local diversity and embarked on an extensive three-year community needs assessment campaign; and 3) DCI was one of the fifteen awardees in the first round NCI P30 supplements (2017) to assess the cancer risks and needs of its catchment area. DCI focuses significant effort on Community Outreach and Engagement (COE) including the 2012 launch of the DCI Office of Health Equity (OHE). Through these coordinated efforts DCI has identified prostate, lung, high-risk breast cancer, and GI cancers including colorectal and stomach, which are either major CA cancer burdens and/or disproportionately affect minority populations, as ?priority? target cancers in the next grant period. Tobacco, obesity and infectious agents were identified as major risk factors and cancer disparities identified as a major crosscutting challenge. This analysis guides our community engagement, community-based interventions, cancer care services, cancer health policy advocacy and research. DCI members conduct ground-breaking, multi-level research on these cancers and risk factors including research directed at understanding the social, structural and biological drivers of cancer disparities, as well as developing and implementing interventions. DCI COE is overseen by DCI?s Deputy Director, Steven Patierno, a nationally recognized expert in cancer disparities research and intervention. He works closely with Nadine Barrett, DCI Associate Director for COE, who also holds a joint DCI-CTSA sponsored position of Director of ?Alliances for Community Engagement and Stakeholder Strategy? (ACESS).
The Specific Aims for the next five years of DCI COE are: 1) to monitor the cancer-relevant needs of our Catchment Area to inform research relevant to our catchment area?s needs; 2) to perform research relevant to our catchment area?s needs and enhance the impact of our Cancer Center?s research to our Catchment Area; 3) to engage our Catchment Area communities in evidence-based strategies for cancer prevention, screening, treatment and outcomes research, with particular emphasis on underserved populations; 4) to extend DCI?s reach within and beyond our catchment area, through affiliates and other networks that bring DCI?s expertise to bear on wider populations, rural populations, and global cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014236-46
Application #
9853613
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
46
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784

Showing the most recent 10 out of 513 publications